The DOI matches its OpenAlex record; 11 of the 11 references it cites were found in a registry or an index.
Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer
Abstract
PURPOSE: We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer. PATIENTS AND METHODS: Patients with urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and had evidence of disease progression were eligible for enrollment. Patients received paclitaxel 80 mg/m(2) by 1-hour intravenous infusion weekly. A cycle of therapy consisted of four weekly treatments. RESULTS: The study enrolled 31 patients. Mean age was 66 years, and 45% of patients had three or more involved metastatic sites. Only 26% of patients had responded to prior chemotherapy. The median number of cycles delivered was three (range, one to eight) at a mean weekly paclitaxel dose of 79 mg/m(2). Three patients achieved a partial response (10%; 95% confidence interval, 0% to 20%). Median time to progression was 2.2 months, and median overall survival time was 7.2 months. Therapy was well tolerated with minimal hematologic toxicity. Grade 3 nonhematologic toxicities were also uncommon. CONCLUSION: Although the overall response rate to weekly paclitaxel in patients with previously treated advanced urothelial cancer was modest, the chemotherapy-refractory nature of the study population should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
Loehrer, P. J., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P., Tannock, I., Raghavan, D., Stuart-Harris, R., Sarosdy, M. F., & Lowe, B. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1066 · Cited by 981
Bajorin, D. F., Dodd, P. M., Mazumdar, M., Fazzari, M., McCaffrey, J. A., Scher, H. I., Herr, H., Higgins, G., & Boyle, M. G. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3173 · Cited by 728
Sternberg, C. N., Yagoda, A., Scher, H. I., Watson, R. C., Ahmed, T., Weiselberg, L. R., Geller, N., Hollander, P. S., Herr, H. W., Sogani, P. C., et al. (1985) · Journal of Urology · doi:10.1016/s0022-5347(17)48996-8 · Cited by 654
Logothetis, C. J., Dexeus, F. H., Finn, L., Sella, A., Amato, R. J., Ayala, A. G., & Kilbourn, R. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.6.1050 · Cited by 607
Seidman, A. D., Hudis, C. A., Albanell, J., Albanel, J., Tong, W., Tepler, I., Currie, V, Moynahan, M. E., Theodoulou, M., Gollub, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3353 · Cited by 378
Roth, B. J., Dreicer, R., Einhorn, L. H., Neuberg, D., Johnson, D. H., Smith, J. L., Hudes, G. R., Schultz, S. M., & Loehrer, P. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2264 · Cited by 317
Fennelly, D., Aghajanian, C., Shapiro, F., O'Flaherty, C., McKenzie, M., O'Connor, C., Tong, W., Norton, L., & Spriggs, D. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.187 · Cited by 242
Cited by
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817323 · Cited by 1,360
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,229
Metadata
- Authors
- Vaughn, D. J., Broome, C. M., Hussain, M., Gutheil, J. C., & Markowitz, A. B.
- Venue
- Journal of Clinical Oncology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2002-02-15
- Volume
- 20
- Issue
- 4
- Pages
- 937-940
- ISSN
- 0732-183X (ISSN-L)
- OpenAlex
- W2092977595
- Cited by
- 269
- References
- 11
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer. https://app.cochat.ai/papers/10.1200/jco.20.4.937
- The paper
- Vaughn, D. J., Broome, C. M., Hussain, M., Gutheil, J. C., & Markowitz, A. B. (2002). Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.4.937
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.